慢性阻塞性肺疾病合并肌少症的发病机制及药物靶点的研究进展  

Research progress on pathogenesis and drug targets of chronic obstructive pulmonary disease complicated with sarcopenia

作　　者：吴春楣 管频[1] WU Chun-mei;GUAN Pin(Health CenterⅤ,Hainan Medical University Hainan Hospital&Hainan General Hospital,Haikou 570311,Hainan,CHINA)

机构地区：[1]海南医科大学附属海南医院&海南省人民医院保健中心四区,海南海口570311

出　　处：《海南医学》2024年第22期3331-3334,共4页Hainan Medical Journal

基　　金：海南省自然科学基金青年项目(编号:820QN388);海南省重点研发项目(编号:ZDYF2024SHFZ106)。

摘　　要：慢性阻塞性肺疾病(慢阻肺)是一种常见的、可预防和治疗的慢性气道疾病。慢阻肺不仅累及肺脏,也能引起多种肺外表现。肌少症是慢阻肺的常见的肺外表现之一。慢阻肺合并肌少症不仅会导致患者的运动耐量和生活质量下降、肺功能恶化,且与慢阻肺的急性加重有关,是其病死率的独立危险因素。目前针对其发病机制的药物靶点治疗手段有限。因此,本综述总结了慢阻肺合并肌少症的发病机制及药物靶点治疗的新进展,希望为慢阻肺合并肌少症的治疗提供新的思路。Chronic obstructive pulmonary disease(COPD)is a common,preventable,and treatable chronic airway disease.COPD not only involves the lungs,but also causes a variety of extrapulmonary manifestations.Sarcopenia is one of the common extrapulmonary manifestations of COPD.COPD combined with sarcopenia will not only lead to the decline of exercise tolerance and quality of life of patients,deterioration of lung function and thus increase the hospitalization rate,but also be associated with acute exacerbation of COPD,which is an independent risk factor for mortality.However,drug-targeted therapies for the pathogenesis of COPD combined sarcopenia are limited.Therefore,this review introduces new advances in the pathogenesis and drug-targeted therapies for the treatment of COPD combined with sarcopenia,hoping to provide new ideas for the treatment of COPD combined with sarcopenia.

关 键 词：慢性阻塞性肺疾病 肌少症 发病机制 药物靶点 

分 类 号：R563[医药卫生—呼吸系统]